Table 2.
Characterization of the AML patients selected for the study.
| Patient ID |
Age | Cytogenetics | Mutations |
|---|---|---|---|
| 1 | 74 | CN | ASXL1, PHF6, SRSF2, STAG2, TET2 |
| 2 | 74 | CN | DNMT3A, PHF6, TET2, U2AF1 |
| 3 | 72 | 46,XY, del[7][q21][13]/46, XY(6)/nonclonal[1] | IDH2, JAK3, SRSF2 |
| 4 | 65 | 47, XYY?c, del(16)(q11.2)[12]/48,idem,+8[5]/47.XYY?c[2]/nonclonal[1] | ASXL1, IDH1, JAK2, U2AF1 |
| 5 | 76 | CN | CCND2, IDH2, NRAS, STAG2 |
| 6 | 77 | CN | IDH1, DNMT3A, NPM1 |
| 7 | 75 | CN | DNMT3A, NPM1 |
| 8 | 57 | 46,XY[19]/nocloncal[1] | DNMT3A, IDH1,NPM1,PTPN11 |
| 9 | 47 | 46,XX[20] | DNMT3A, IDH2,NPM1,FLT3 |
CN, cytogenetically normal